Biotech entity
pharma is the sole category represented across all 1 tracked stories. GC Biopharma is most often covered alongside MAV/06, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. GC Biopharma appears in 1 tracked Biotech story from March 11, 2026.
Last mentioned: Mar 11, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. GC Biopharma is most often covered alongside MAV/06, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. GC Biopharma appears in 1 tracked Biotech story from March 11, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 9 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering GC Biopharma. Shared-story counts are live from our verified record — not editorial picks.
30-Year Review Publication
Comprehensive review paper summarizing three decades of data is published in a peer-reviewed journal.
Barycel Launch
GC Biopharma launches an improved version of its varicella vaccine based on the MAV/06 strain.
Global Expansion
The MAV/06-based vaccine is exported to over 30 countries and integrated into national immunization programs.
Initial Development
GC Biopharma begins the clinical application of the MAV/06 varicella strain.
GC Biopharma has published a comprehensive review paper detailing three decades of clinical and real-world data for its proprietary MAV/06 varicella vaccine strain. This publication underscores the long-term safety and efficacy of the strain, which has been a cornerstone of the company's global vaccine portfolio and international procurement strategy.
GC Biopharma is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
